Lilly’s Experimental Shot Cuts Body Weight by 28% in Study (2)

Nearly half of patients who got a high dose of Eli Lilly & Co.’s next-generation obesity shot lost the equivalent weight of bariatric surgery, further evidence that the treatment could be the company’s most potent weight-loss medicine yet.

In a late-stage trial, patients who could tolerate the highest dose of retatrutide for a year-and-a-half lost 28.3% of their body weight on average, Lilly said in a statement Thursday.

The results met with Wall Street’s expectations. RBC Capital Markets analyst Trung Huynh had said the bar for success would be weight loss of between 28% and 30%. Huynh called the ...